252364-41-3

Basic information

• Product Name: [2-methoxy-3-[(1,1-dimethylethyldiphenylsilyl)oxy]phenyl][1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methanone
• Synonyms: [2-methoxy-3-[(1,1-dimethylethyldiphenylsilyl)oxy]phenyl][1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methanone
• CAS NO: 252364-41-3
• Molecular Weight: 595.829
• Mol File: 252364-41-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: [2-methoxy-3-[(1,1-dimethylethyldiphenylsilyl)oxy]phenyl][1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methanone(CAS DataBase Reference)
• NIST Chemistry Reference: [2-methoxy-3-[(1,1-dimethylethyldiphenylsilyl)oxy]phenyl][1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methanone(252364-41-3)
• EPA Substance Registry System: [2-methoxy-3-[(1,1-dimethylethyldiphenylsilyl)oxy]phenyl][1-[2-(4-fluorophenyl)ethyl]-4-piperidinyl]methanone(252364-41-3)

Safety Data

• Hazardous Substances Data: 252364-41-3(Hazardous Substances Data)

Upstream product

• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 108534-61-8 (2-methoxyphenoxy)-(1,1-dimethylethyl)diphenylsilane 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 90-05-1 2-methoxy-phenol 
• 311348-74-0 4-[2-methoxy-3-[(1,1-dimethylethyl)diphenylsilyl]oxybenzoyl]-1-piperidinecarboxylic acid 1,1-dimethylethyl ester 
• 139290-70-3 tert-butyl 4-(methoxy(methyl)carbamoyl)piperidine-1-carboxylate 
• 332-42-3 (2-bromoethyl)-4-fluorobenzene 
• 175553-31-8 1-[2-(4-fluorophenyl)-ethyl]-piperidine-4-carboxylic acid ethyl ester 
• 1126-09-6 4-carbethoxypiperidine 
• 175553-32-9 1-[2-(4-fluorophenyl)ethyl]-4-piperidinecarboxylic acid N-methoxy N-methyl amide 

Downstream Products

• 252364-42-4 (+/-)-α-[2-methoxy-3-[(1,1-dimethylethyldiphenylsilyl)oxy]phenyl]-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanone 

Relevant articles and documents

Design, Synthesis, and Pharmacological Characterization of Heterobivalent Ligands for the Putative 5-HT2A/mGlu2Receptor Complex

We report the synthesis of the first series of heterobivalent ligands targeting the putative heteromeric 5-HT2A/mGlu2 receptor complex, based on the 5-HT2A antagonist MDL-100,907 and the mGlu2 ago-PAM JNJ-42491293. The functional properties of monovalent and heterobivalent ligands were characterized in 5-HT2A-, mGlu2/Gqo5-, 5-HT2A/mGlu2-, and 5-HT2A/mGlu2/Gqo5-expressing HEK293 cells using a Ca2+ imaging assay and a [3H]ketanserin binding assay. Pronounced functional crosstalk was observed between the two receptors in 5-HT2A/mGlu2 and 5-HT2A/mGlu2/Gqo5 cells. While the synthesized monovalent ligands retained the 5-HT2A antagonist and mGlu2 ago-PAM functionalities, the seven bivalent ligands inhibited 5-HT-induced responses in 5-HT2A/mGlu2 cells and both 5-HT- and Glu-induced responses in 5-HT2A/mGlu2/Gqo5 cells. However, no definitive correlation between the functional potency and spacer length of the ligands was observed, an observation substantiated by the binding affinities exhibited by the compounds in 5-HT2A, 5-HT2A/mGlu2, and 5-HT2A/mGlu2/Gqo5 cells. In conclusion, while functional crosstalk between 5-HT2A and mGlu2 was demonstrated, it remains unclear how these heterobivalent ligands interact with the putative receptor complex.

Total synthesis and evaluation of [18F]MHMZ

Radiochemical labeling of MDL 105725 using the secondary labeling precursor 2-[18F]fluoroethyltosylate ([18F]FETos) was carried out in yields of ～90% synthesizing [18F]MHMZ in a specific activity of ～50 MBq/nmol with a sta